The groundbreaking rise of Viagra has firmly established as a example of pharmaceutical success, but its future within the broader industry now triggers questions about future yields . Copycat versions are eroding exclusivity , leading to anxieties that investing in companies closely tied to Viagra's previous standing could be a dangerous strategy,